Britain needs 6,000 more volunteers to take Merck's COVID-19 pill mainstreamProactive Investors • 01/25/22
Britain To Test Merck - Ridgeback Biotherapeutics' COVID-19 Antiviral Pill In Hospitalized PatientsBenzinga • 01/24/22
Results From Pivotal Phase 3 KEYNOTE-775/Study 309 Trial of KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Advanced Endometrial Carcinoma Published in the New England Journal of MedicineBusiness Wire • 01/20/22
Merck's Keytruda Manages To Cross The Finish Line In Liver Cancer Confirmatory TrialBenzinga • 01/19/22
Merck's KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Versus Placebo in Certain Patients With Advanced Hepatocellular Carcinoma (HCC) Previously Treated With SorafenibBusiness Wire • 01/18/22
Merck Animal Health's Third Veterinarian Wellbeing Study Reveals Increased Health Challenges and Psychological Distress Among VeterinariansPRNewsWire • 01/18/22
Merck and Ridgeback Biotherapeutics to supply 3 million doses of COVID antiviral to Unicef in 2022Market Watch • 01/18/22
Merck and Ridgeback Announce Supply Agreement with UNICEF for Molnupiravir, an Investigational Oral Antiviral COVID-19 MedicineBusiness Wire • 01/18/22
Week 3 MDA Breakout Stocks - January 2022: Short-Term Picks To Give You An EdgeSeeking Alpha • 01/15/22